Halozyme Therapeutics, Inc.
US ˙ NasdaqGS ˙ US40637H1095

SecurityHALO / Halozyme Therapeutics, Inc.
InstitutionAxa S.a.
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Axa S.a. closes position in HALO / Halozyme Therapeutics, Inc.

On November 14, 2025 - Axa S.a. filed a 13F-HR form disclosing ownership of 0 shares of Halozyme Therapeutics, Inc. (US:HALO) valued at $0 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 14, 2025 disclosing 123,012 shares of Halozyme Therapeutics, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-11-14 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 0 -100.00 0
2025-08-14 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 123,012 512 0.42 6,399 -18.13 0.0184
2025-05-15 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 122,500 -9,391 -7.12 7,817 23.97 0.0257
2025-02-14 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 131,891 23,835 22.06 6,306 1.94 0.0192
2024-11-14 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 108,056 108,056 6,185 0.0183
2025-02-25 2024-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 0 -135,203 -100.00 0 -100.00
2024-08-14 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 0 -135,203 0
2024-05-15 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 135,203 84,869 168.61 5,500 195.70 0.0165
2024-07-16 2023-12-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 50,334 24,834 97.39 1,860 90.97 0.0060
2024-02-14 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 50,334 24,834 1,860 0.0036
2023-11-14 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 25,500 1,800 7.59 974 14.05 0.0034
2023-08-14 2023-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 23,700 -14,125 -37.34 855 -40.86 0.0028
2023-05-15 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 37,825 2,153 6.04 1,445 -28.83 0.0050
2023-02-14 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 35,672 -21,000 -37.06 2,030 -9.42 0.0073
2023-02-14 2022-09-30 13F/A-1 Halozyme Therapeutics COM 40637H109 56,672 56,672 2,241 0.0088
2022-11-14 2022-09-30 13F Halozyme Therapeutics COM 40637H109 56,672 56,672 2,241 0.0088
2022-08-15 2022-06-30 13F Halozyme Therapeutics COM 40637H109 0 -5,200 -100.00 0 -100.00
2023-02-14 2022-03-31 13F/A-1 Halozyme Therapeutics COM 40637H109 5,200 -86,500 -94.33 207 -94.39 0.0006
2022-05-13 2022-03-31 13F Halozyme Therapeutics COM 40637H109 5,200 -86,500 207 0.0006
2022-02-14 2021-12-31 13F Halozyme Therapeutics COM 40637H109 91,700 -34,000 -27.05 3,687 -27.89 0.0094
2021-11-15 2021-09-30 13F Halozyme Therapeutics COM 40637H109 125,700 125,700 5,113 0.0143
2021-05-14 2021-03-31 13F Halozyme Therapeutics COM 40637H109 0 -87,900 -100.00 0 -100.00
2021-02-12 2020-12-31 13F Halozyme Therapeutics COM 40637H109 87,900 87,900 3,754 0.0118
2020-02-15 2019-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -25,000 -100.00 0 -100.00
2021-02-12 2019-09-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 25,000 -411,419 -94.27 388 -94.83 0.0015
2019-11-14 2019-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 25,000 -411,419 388 1,546.2047
2021-02-12 2019-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 436,419 8,202 1.92 7,498 8.76 0.0293
2019-08-13 2019-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 436,419 8,202 7,498 29,404.0023
2019-05-14 2019-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 428,217 0 0.00 6,894 10.04 0.0269
2019-02-13 2018-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 428,217 0 0.00 6,265 -19.48 0.0273
2018-11-08 2018-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 428,217 37,108 9.49 7,781 17.93 0.0285
2018-08-13 2018-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 391,109 391,109 6,598 0.0253
2016-05-13 2016-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -44,060 -100.00 0 -100.00
2016-02-12 2015-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 44,060 -32,540 -42.48 764 -25.75 0.0033
2015-11-13 2015-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 76,600 76,600 0.00 1,029 0.0042
2015-02-13 2014-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -117,208 -100.00 0 -100.00
2014-11-13 2014-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 117,208 -753 -0.64 1,067 -8.41 0.0046
2014-08-13 2014-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 117,961 -4,745 -3.87 1,165 -25.22 0.0048
2014-05-13 2014-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 122,706 6,389 5.49 1,558 -10.67 0.0068
2014-02-13 2013-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 116,317 5,786 5.23 1,744 42.95 0.0078
2013-11-13 2013-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 110,531 22,255 25.21 1,220 74.04 0.0060
2013-08-12 2013-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 88,276 88,276 701 0.0037
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.